would like to highlight Nutra Pharma Corp.
), a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma’s intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.
In the company’s news,
Nutra Pharma Corporation (OTCQB: NPHC) has announced that it will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference, which will take place at The Ritz-Carlton in Miami on South Beach on February 22, 2016. As a presenter, Nutra Pharma will be provided with a 30-minute time slot with which to present to an audience of investors and industry professionals. The company’s management team is also expected to be available for one-on-one meetings with institutional investors attending the event.
To view a complete list of presenting companies, visit http://steconference.com/presenting-companies
This announcement caps off what has been an eventful week for Nutra Pharma. On Tuesday, the biotechnology company announced the first of several growth steps expected to expand its core business strength, as well as its reach into important commercial markets. As part of this strategy, Nutra Pharma added Thomas W. Northrop, a member of New York-based management advisory and investment firm Tri-State Capital Partners, LLC, to its expanded management team. Northrop will serve as the company’s senior commercial development officer moving forward. From this position, he is expected to lead new marketing efforts in healthcare, governmental and military entities; aging athletes; and the elderly, as well as the completion of scientifically rigorous pain relief trials in multiple settings.
“The addition of Tom Northrop and TriState’s arrival as part of Nutra Pharma’s expanded management team are the first steps in the company’s growth strategy for 2016,” Rik J. Deutsch, chief executive officer of Nutra Pharma, stated in Tuesday’s news release. “With Tri-State’s support, we now have the tools and a depth of resources that will allow for expansion into multiple markets, as well as to help accelerate the development and deployment of our prescription drug candidates.”
Additional information regarding Nutra Pharma’s 2016 growth plans is expected to be announced in the coming weeks. With opioid abuse at record levels and heightened recognition of the potential dangers of misusing acetaminophen and non-steroidal anti-inflammatory drugs (NSAID), such as ibuprofen, the company will look to leverage its position in the biotechnology industry in order to capitalize on sizable global markets for innovative products addressing chronic pain.
Nutra Pharma operates as a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases – including multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain. The company also markets drug products for the treatment of chronic pain under the Nyloxin® and Pet Pain-Away brands.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.